


10th European
Multidisciplinary
Colorectal Cancer
Congress

**Sponsor
prospectus**



**EMCCC
2022**

**20-21
MARCH
2022
ONLINE**

www.emccc2022.org

INVITATION

It is with great pleasure to invite you to participate in the **10th European Multidisciplinary Colorectal Cancer Congress 2022!**

The **European Multidisciplinary Colorectal Cancer Congress (EMCCC)** is the European conference that truly provides a platform for in-depth multidisciplinary interaction among the various research areas involved.

The Dutch Colorectal Cancer Group (DCCG) has taken the initiative for the EMCCC since 2001. The conference in 2022 builds upon eight previous successful multidisciplinary conferences on colorectal cancer which were held in the Netherlands, Germany, Portugal and France. The EMCCC offers an intimate scientific/educational environment for more than 500 participants.

Colorectal cancer is one of the most common types of malignancies and much progress has been made in recent years in understanding the biology and treatment of this disease. These developments encompass almost the full research area including genetics, biology, pathology/prognostic markers, surgery, screening, systemic treatment, radiotherapy, and imaging. This implies that both pre-clinical and clinical research is becoming much more multidisciplinary oriented.

The conference will offer parallel sessions on:

- Systemic treatment of metastasized CRC
- Early (T1-T2) CRCs
- Translational research
- (neo)Adjuvant treatment of CRC
- Local treatment of metastasized CRC
- Sponsored sessions

The meeting will be hosted online from 20-21 March 2022.

We look forward to meet you online!

ABOUT THE COLORECTAL WORKING GROUPS

The European Colorectal Cancer Working Groups offer an excellent infrastructure for the performance of multicentre clinical studies in patients with colorectal cancer. Examples are the TME, PROCTOR/SCRIPT, and CAIRO studies. The success of these studies is largely due to the collaboration between the relevant groups and disciplines, such as surgery, radiotherapy, medical oncology, and pathology, as well as the support from data centres such as the regional trial offices of the Comprehensive Cancer Centres. This allows the conduct of large randomized studies with objectives that are in favor of the treatment of colorectal cancer patients.

The primary goal of the EMCCC is to exchange clinical data to improve the quality of diagnosis and treatment of patients with colorectal cancer on an international level.

ORGANIZING COMMITTEE

Leon Moons, chair
Jeroen Buijsen
Mariam Koopman
Hans de Wilt

INTERNATIONAL SCIENTIFIC COMMITTEE

Pim Burger	Miangela Lacie
Paolo Delrio	Maurice Loughrey
Alfredo Falcone	Fotios Loupakis
Remond Fijneman	Maria Pellise
Amyr Hajj	Femke Peters
Cesare Hassan	Paolo Sammartino
Roel Hompes	Rolf Sijmons
Karin Horsthuis	Petur Snaebjornsson
Martijn Intven	Alberto Sobrero
Lene Iversen	Antonio Sommariva
Jeremie Jacques	Henk Verheul

COLORECTAL CANCER WORKING GROUPS

Danish Colorectal Cancer Group
Dutch Colorectal Cancer Group
EORTC GI group
French GRECCAR Study Group
German AIO group
Italian Intergroup structure and projects
National Cancer Research Institute - Colorectal Cancer Clinical Studies Group UK
Portuguese GICD study group
Spanish TTD Group

CONGRESS & EXHIBITION ORGANIZERS

Congress Care

PO Box 440
5201 AK 's-Hertogenbosch
The Netherlands
Tel. +31-73-690 1415
info@congresscare.com
www.congresscare.com



PROGRAM AT A GLANCE


SUNDAY 20 MARCH 2022

	Systemic treatment of metastasized CRC
	Early (T1-T2) CRCs
	Translational research
	(neo)adjuvant treatment of CRC
	local treatment of metastasized CRC (liver/lung/peritoneal)

TIME LINE	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM 5
08:00-08:45					
08:30	Welcome				
09:00-10:00	State of the art Surgery				
09:00-09:15	Value of CRS and HIPEC				
09:15-09:30					
09:30-09:45	Rectal surgery anno 2022				
09:45-10:00					
Pauze					
10:15-11:00	Liver metastasis-induction chemotherapy	Prognostic value of histological features on disease recurrence	Peritoneal metastasis	What is the ideal assesment of an early rectal cancer- case based discussion	Clinical applications of circulating tumor DNA
10:15-10:30	Growth patterns of livermetastasis	Value of tumor deposits on disease recurrence	pT4 definition and risk PM, signet cell carcinoma, PM and CRS/HIPEC	Case 1	ctDNA as biomarker to detect minimal residual disease
10:30-10:45	Is there an optimal systemic induction regimen in patients with potentially resectable livermetastases?	Value of lymph node metasis on disease recurrence	The role of Micro-Satellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases	Case 2	ctDNA as biomarker to guide therapy selection
10:45-11:00	Hepatic artery infusion pump chemotherapy-SUNSET OR SUNRISE	Recurrence of disease from a biological perspective: CMS score/Immunoscore	Imaging of peritoneal metastases.	Discussion on a proposed assesment algorithm	ctDNA as biomarker for monitoring treatment response
11:00-12:15	Oligometastatic disease	Adjuvant treatment of high risk Stage II CRC	local treatment of liver metastasis	Histological evaluation of T1 CRCs	Organoids for therapy selection
11:00-11:15	Sabr COMET Phase III trial	Neoadjuvant chemotherapy for colon cancer	Liver transplantation for liver metastasis	Controversies in assssing T1 CRCs- case based discussion	Patient-derived organoids for forward and reverse translational cancer research
11:15-11:30	Cairo V	Who needs adjuvant chemotherapy for colon cancer	Rectal cancer with resectable liver metastasis		Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
11:30-11:45	LUNA	Follow-up after surgery of high risk CRCs-spreker Primrose	How far can you go with liver resection		Selected abstracts
11:45-12:15	Selected Abstracts	Selected Abstracts	Selected Abstracts	Selected Abstracts	Selected Abstracts
12:15-13:00	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions
13:00-14:00	Treatment of T1 CRCs				
13:00-13:15	Real life Recognition of T1 CRCs				
13:15-13:30	state of the art of Local excision of T1 CRCs				
13:30-14:00	How to treat high risk colon T1 CRC				
14:15-15:00	New developments Palliative systemic therapy	Treatment of recurrent rectal cancer	Treatment of liver metastasis with radio-embolisation (Marnix Lam)	Optical diagnosis- Selection of cases for en bloc resections	Biology of metastasis
14:15-14:30	Triple therapy for RAS-mutation	Extensive surgery and IORT in recurrent rectal cancer	Introduction to radioembolization- spreker:	When to perform en bloc resections (cut-offs)	Chromosomal instability and the tumor microenvironment
14:30-14:45	HER2 remming	The role of neo-adjuvant treatment in locally recurrent rectal cancer	Clinical indications and outcomes	When to go for primary surgery (cut-offs)	Genetic diversity in CRC metastases
14:45-15:00	Herintroductie van EGFR remming (CHRONOS studie)	Radiotherapy and systemic therapy for recurrent rectal cancer	Future prospects of radioembolization	AI instead of optical diagnosis by the endoscopist	Selected abstracts
Pauze					
15:15-16:00	Predicting treatment response	Organ preservation for early (T2-T3) rectal cancer		TRIALS for T1 CRCs	
15:15-15:30	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival	neoadjuvant radiotherapy for organ preservation		What are the important endpoints	imaging CRC metastasis
15:30-15:45	WGS reveals prior treatment effects	neoadjuvant chemoradiation for organ preservation		PROMS for T1 CRCs	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver
15:45-16:30	Personalized treatmen in the clinical setting - how to do it?	neoadjuvant systemic treatment for organ preservation		What is the optimal study design	Selected abstracts
16:00-16:30	Selected Abstracts	Selected Abstracts		Selected Abstracts	Selected Abstracts
Pauze					
16:45-17:30	Key note lecture				
	Local treatment of liver metastasis				

PROGRAM AT A GLANCE

MONDAY 21 MARCH 2022



- Systemic treatment of metastasized CRC
- Early (T1-T2) CRCs
- Translational research
- (neo)adjuvant treatment of CRC
- local treatment of metastasized CRC (liver/lung/peritoneal)


TIME LINE	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM 5
08:00-08:45	Breakfast sessions	Breakfast sessions	Breakfast sessions	Breakfast sessions	Breakfast sessions
09:00-10:00					
09:00-09:15	WGS - routine diagnostics?				
09:15-09:30					
09:30-09:45	ctDNA - routine diagnostics?				
09:45-10:00					
Pauze					
10:15-11:00		Clinical genetics	CRC and IBD-case presentation	Risk estimation of adverse oncological outcome in T1 CRC	Challenges and benefits of prospective patient accrual for translational research
10:15-10:30	Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer	Chemoprevention in Lynch syndrome-CAPP trials	The work-up of colitis associated dysplasia	Epidemiology of lymph node metastasis and recurrences	How to accrue all CRC patients for translational research
10:30-10:45	Integrated Omics of Metastatic Colorectal Cancer	Type of surgery in Lynch patients	Local treatment versus segmental resection	Pathways to development of metastasis (20 min)	Challenges of intl trials [FOxTROT]
10:45-11:00	Clinical relevance of ex-vivo drug testing	MSI-tests- new technical developments	Extend of surgery for IBD related dysplasia/ cancer	What is the optimal model for risk assessment of T1 CRCs	Modeling health benefit
11:00-12:15	Rectal recurrences	Rectal surgery- the preferred modality	T4 CRCs (diagnosis and biology)	Alternative strategies for completion surgery	Capture, view, query clinical, imaging and molecular data
11:00-11:15	Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy	taTME	Selection of T4 tumors based on CT scan	R1/Rx without risk factors: completion surgery or local scar excision	Capturing clinical images: XNAT
11:15-11:30	Induction therapy: Start with radiotherapy or chemotherapy?	Robotic surgery	Pathways to peritoneal metastasis and potential targets of treatment	High risk T1 rectal cancer- intensive surveillance or completion surgery	Capturing pathology images: SlideScore
11:30-11:45	Salvage surgery	Laparoscopic surgery	Surgical aspects of multivisceral resections	Adjuvant radiotherapy for high risk rectal cancers	cBioPortal - demo
11:45-12:15	Selected Abstracts	Selected Abstracts	Selected abstracts	Selected Abstracts	
12:15-13:00	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions	Sponsored Lunch sessions
13:00-14:00	Chemotherapy & Immunotherapy				
13:00-13:20	Latest developments in systemic therapy				
13:20-13:40	Immunotherapy				
13:40-14:00	KRAS inhibition in mCRC				
14:15-15:00	Immunotherapy	Abdominal Imaging- the new era	Peritoneal metastases	Local excision of T1 CRC which plane of resection	Novel biomarkers for early detection
14:15-14:30	TGF-β inhibition to potentiate immunotherapy	Staging rectal cancer with MRI- beyond the TNM classification	Preclinical/basic aspects and mechanisms of PM or IP drug delivery (Ceelen)	Submucosa	Novel biomarkers for early detection
14:30-14:45	Neo-adjuvant immunotherapy (NICHE trial)	functional imaging- FAPI scan	Synchronous and metachronous PM; Late effects after CRS+HIPEC (Iversen)	Intermuscular	CRC screening
14:45-15:00	The Intestinal Microbiota in Colorectal Cancer	Prediction of lymph node metastasis	Update on clinical trials	Full thickness	Selected Abstracts
Pauze				Discussion with online questions	
15:15-16:30	Colorectal lung metastases	T4 tumors and adjuvant treatment (Tanis)	AI in pathology - the new predictor of survival	New developments in local resection techniques	AI in pathology - the new predictor of survival
15:15-15:30	Local treatment of lung metastases Yes or NO (Battle)	Prevention of peritoneal metastases from colorectal cancer	Pathomics- Stage II/III CRC	Pattern of recurrence	Pathomics- Stage II/III CRC
15:30-15:45			Pathomics-liver metastasis	Surveillance strategies for the Colon	Pathomics-liver metastasis
15:45-16:00		Is there a place for Prophylactic HIPEC	pathomics and biology-	Surveillance strategies for the rectum	Pathomics and biology-
16:00-16:30	Selected Abstracts	Is there a role for second look surgery	AI in pathology	Selected Abstracts	AI in pathology
pauze					
16:45-17:30	Key note lecture				
	Neo(adjuvant) treatment of colon carcinomas	Miriam Chalabi			

GENERAL INFORMATION



PARTICIPANTS AND TARGET AUDIENCE

We are inviting a wide range of health care professionals, working in the field of colorectal cancer with an interest in: medical oncology, surgical oncology, radiation oncology, pathology, gastroenterology, imaging, radiology, basic science and genetics.



CONGRESS LANGUAGE

The official language of the Congress is English.



TIMING

The EMCCC will start Sunday morning 20 March 2022 with a plenary program followed by 5 parallel sessions on the main topics. Monday will offer a comparable schedule. There is ample time for sponsored sessions, workshops and video sessions.

SPONSORSHIP PACKAGES

The European Multidisciplinary Colorectal Cancer Congress offers many unique sponsorship opportunities designed to fit any budget or need. Please find below some packages including sponsored symposium, followed by individual sponsored items.

SPONSOR PACKAGE 1 GOLD

Total investment: € 16.950,-

- Possibility to conduct a 45 min sponsored session
- 10 unique log-ins to join the live online EMCCC 2022 meeting
- Sponsor commercial (max 45 sec) during all breaks
- Virtual Booth
- Awareness as Virtual Gold Partner (incl. logo + link) on the EMCCC 2022 website
- Awareness as Virtual Gold Partner on pre- and post-mailings to EMCCC 2022 delegates
- Lead retrieval

SPONSOR PACKAGE 2 SILVER

Total investment: € 11.950,-

- Possibility to conduct a 30 min sponsored session or video session
- 6 unique log-ins to join the live online EMCCC 2022 meeting
- Sponsor commercial (max 30 sec) during all breaks
- Virtual Booth
- Awareness as Virtual Silver Partner (incl. logo + link) on the EMCCC 2022 website
- Awareness as Virtual Silver Partner on pre- and post-mailings to EMCCC 2022 delegates
- Lead retrieval

SPONSOR PACKAGE 3 BRONZE

Total investment: € 6.950,-

- Possibility to conduct a 15 min sponsored session or video session
- 4 unique log-ins to join the live online EMCCC 2022 meeting
- Sponsor commercial or 3 slides (max 15 sec) during all breaks
- Virtual Booth
- Awareness as Virtual Bronze Partner (incl. link) on the EMCCC 2022 website
- Awareness as Virtual Bronze Partner on pre- and post-mailings to EMCCC 2022 delegates
- Lead retrieval

PRE-CONGRESS EBLAST

The Congress Organizer will send out one eBlast to all pre-registrants. Promote your booth and/or symposium prior to the Congress.

HTML provided by supporter € 1.500,-

(No HTML development needed)

HTML development € 2.000,-

(Content only provided, congress organizer will design e-mail)

WE ARE HAPPY TO DISCUSS TAILOR MADE SPONSOR PACKAGES PLEASE CONTACT THE CONGRESS SECRETARIAT

SPONSOR APPLICATION FORM

DETAILS II logistic & practical matters

Company Telephone

Contact person E-mail

CONTACT DETAILS II invoicing & contracting

Company Telephone

Contact person E-mail

Address for correspondence PO-number (if applicable)

Signature VAT-number
(European Community based companies only)

PROCEDURE

- 1) Please mark the event(s) you would like to sponsor
- 2) After receipt of the application form, you will receive a confirmation and an invoice for the requested items for a non-refundable deposit of 50% of the total amount. The remaining 50% of the total amount due will be invoiced in December 2021.
- 3) The total amount has to be settled before 1 February 2022. Cancellation fee of 50% of the total amount will be charged up until 6 months before the congress. There after the full amount will be charged in the event of cancellation.

PACKAGES

<input type="checkbox"/> Packages I	€ 16.950,-
<input type="checkbox"/> Packages I I	€ 11.950,-
<input type="checkbox"/> Packages III	€ 6.950,-

INDIVIDUAL SPONSOR ITEMS

<input type="checkbox"/> Pre-congress eBlast		
o HTML provided	€ 1.500,-	Quantity
o HTML development	€ 2.000,-	Quantity
Total amount	€	

FOR MORE INFORMATION ON SPONSORSHIP OPPORTUNITIES, PLEASE CONTACT:

Rob Zikkenheimer & Daphne Hilgers
Congress Care
Europalaan 16
P.O. Box 440
5201 AK 's-Hertogenbosch
Tel. +31(0)73 6901415
r.zikkenheimer@congresscare.com
d.jacobs@congresscare.com

www.EMCCC2022.org